American Research & Management Co. boosted its holdings in Balchem Co. (NASDAQ:BCPC) by 5.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,025 shares of the basic materials company’s stock after purchasing an additional 325 shares during the period. American Research & Management Co.’s holdings in Balchem were worth $756,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in BCPC. CI Investments Inc. grew its holdings in Balchem by 444.0% during the fourth quarter. CI Investments Inc. now owns 272 shares of the basic materials company’s stock valued at $31,000 after purchasing an additional 222 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Balchem in the third quarter worth about $56,000. Veriti Management LLC bought a new stake in shares of Balchem in the fourth quarter valued at approximately $120,000. 6 Meridian purchased a new stake in shares of Balchem during the 4th quarter valued at approximately $205,000. Finally, Bailard Inc. purchased a new position in Balchem in the 4th quarter valued at approximately $217,000. Institutional investors own 85.01% of the company’s stock.
Shares of BCPC traded down $0.67 during midday trading on Thursday, reaching $120.20. The stock had a trading volume of 1,597 shares, compared to its average volume of 127,352. The company has a current ratio of 3.95, a quick ratio of 2.82 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of 47.33 and a beta of 0.54. The company’s 50-day moving average is $124.20 and its 200 day moving average is $112.84. Balchem Co. has a 12-month low of $79.75 and a 12-month high of $132.50.
BCPC has been the topic of several recent research reports. Stephens upgraded Balchem from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $100.00 to $140.00 in a research report on Monday, March 1st. HC Wainwright increased their price objective on Balchem from $126.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, March 1st. Finally, Zacks Investment Research upgraded Balchem from a “strong sell” rating to a “strong-buy” rating and set a $144.00 price target on the stock in a research report on Friday, April 2nd.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Further Reading: What sectors are represented in the Nikkei Index?
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.